Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD

• To evaluate the persistence of effect of RGX-314 on best corrected visual acuity (BCVA)

• Mean change from baseline (ie, prior to RGX-314 administration in the parent study) in BCVA

Time frame: 5 years inclusive of parent study

• To evaluate the persistence of effect of RGX-314 on central retinal thickness (CRT), as measured by spectral domain-optical coherence tomography (SD-OCT)

• Mean change from baseline (ie, prior to RGX-314 administration in the parent study) in CRT as measured by SD-OCT

Time frame: 5 years inclusive of parent study

• To assess the need for supplemental anti-vascular endothelial growth factor (anti-VEGF) therapy

• Mean number of supplemental anti-VEGF injections based on chart review

Time frame: 5 years inclusive of parent study

• To assess the need of clinic visits for management of nAMD

• Mean number of retina specialist visits attended for nAMD based on chart review

Time frame: 5 years inclusive of parent study